JP2017511313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511313A5 JP2017511313A5 JP2016558714A JP2016558714A JP2017511313A5 JP 2017511313 A5 JP2017511313 A5 JP 2017511313A5 JP 2016558714 A JP2016558714 A JP 2016558714A JP 2016558714 A JP2016558714 A JP 2016558714A JP 2017511313 A5 JP2017511313 A5 JP 2017511313A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- braf
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 62
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 28
- 230000035772 mutation Effects 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 19
- 239000007962 solid dispersion Substances 0.000 claims description 17
- -1 1- (6-Amino-5-chloropyrimidine-4-carboxamido) ethyl Chemical group 0.000 claims description 15
- 102100039788 GTPase NRas Human genes 0.000 claims description 14
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 14
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 13
- 229920001577 copolymer Polymers 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- GGNIKGLUPSHSBV-UHFFFAOYSA-N thiazole-5-carboxamide Chemical compound NC(=O)C1=CN=CS1 GGNIKGLUPSHSBV-UHFFFAOYSA-N 0.000 claims description 7
- 101150073096 NRAS gene Proteins 0.000 claims description 6
- 101150048834 braF gene Proteins 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 4
- 229920001531 copovidone Polymers 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 230000000144 pharmacologic effect Effects 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000013610 patient sample Substances 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 230000009477 glass transition Effects 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461970595P | 2014-03-26 | 2014-03-26 | |
| US61/970,595 | 2014-03-26 | ||
| US201462048527P | 2014-09-10 | 2014-09-10 | |
| US62/048,527 | 2014-09-10 | ||
| UY36046 | 2015-03-25 | ||
| PK162/2015 | 2015-03-25 | ||
| PK16215 | 2015-03-25 | ||
| UY0001036046A UY36046A (es) | 2014-03-26 | 2015-03-25 | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
| PCT/US2015/022792 WO2015148828A1 (en) | 2014-03-26 | 2015-03-26 | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511313A JP2017511313A (ja) | 2017-04-20 |
| JP2017511313A5 true JP2017511313A5 (enExample) | 2018-04-26 |
| JP6571105B2 JP6571105B2 (ja) | 2019-09-04 |
Family
ID=57215543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558714A Active JP6571105B2 (ja) | 2014-03-26 | 2015-03-26 | 汎ｒａｆキナーゼ阻害剤の薬学的製剤、その調製プロセス、及び使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10426782B2 (enExample) |
| EP (1) | EP3122334B1 (enExample) |
| JP (1) | JP6571105B2 (enExample) |
| CN (1) | CN106456787B (enExample) |
| BR (1) | BR112016022219B1 (enExample) |
| CA (1) | CA2943808C (enExample) |
| CO (1) | CO2016003340A2 (enExample) |
| CR (1) | CR20160483A (enExample) |
| DO (1) | DOP2016000254A (enExample) |
| EA (1) | EA031190B1 (enExample) |
| EC (1) | ECSP16084317A (enExample) |
| ES (1) | ES2744298T3 (enExample) |
| GE (1) | GEP20186932B (enExample) |
| MA (1) | MA39765A (enExample) |
| PE (1) | PE20170773A1 (enExample) |
| UY (1) | UY36046A (enExample) |
| WO (1) | WO2015148828A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190117652A1 (en) * | 2014-12-23 | 2019-04-25 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and taxanes |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| US11760803B2 (en) | 2016-03-24 | 2023-09-19 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| WO2017165491A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| EP4065122A4 (en) * | 2019-11-27 | 2023-12-27 | Day One Biopharmaceuticals, Inc. | Solid dispersion of pan-raf kinase inhibitor |
| CN117042772A (zh) * | 2020-11-06 | 2023-11-10 | 首日生物制药公司 | 用于治疗低级别胶质瘤的raf抑制剂 |
| JP2023548600A (ja) * | 2020-11-06 | 2023-11-17 | デイ ワン バイオファーマシューティカルズ， インコーポレイテッド | 低グレード神経膠腫を処置するためのｒａｆインヒビター |
| EP4294400A4 (en) * | 2021-02-19 | 2025-01-01 | Day One Biopharmaceuticals, Inc. | COMBINATION OF RAF INHIBITOR AND MEK INHIBITOR |
| EP4404978A4 (en) * | 2021-09-22 | 2025-09-10 | Sirnaomics Inc | IMPROVED METHODS FOR PREPARING NANOPARTICLE COMPOSITIONS CONTAINING HISTIDINE-LYSINE COPOLYMERS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US5346994A (en) | 1992-01-28 | 1994-09-13 | Piotr Chomczynski | Shelf-stable product and process for isolating RNA, DNA and proteins |
| DE19509807A1 (de) * | 1995-03-21 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen |
| US20050220865A1 (en) | 2004-04-02 | 2005-10-06 | Koleng John J | Compressed composition comprising magnesium salt |
| ES2429097T3 (es) | 2005-12-16 | 2013-11-13 | Hanmi Science Co., Ltd. | Dispersión sólida que comprende un principio activo de bajo punto de fusión y comprimido para administración oral que la comprende |
| KR100767349B1 (ko) * | 2006-08-01 | 2007-10-17 | 삼천당제약주식회사 | 페노피브레이트를 함유하는 경구용 약제 조성물 및 그의제조방법 |
| WO2008063910A2 (en) | 2006-11-08 | 2008-05-29 | Novavax, Inc. | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
| WO2008114859A1 (ja) * | 2007-03-22 | 2008-09-25 | Astellas Pharma Inc. | ピラゾール誘導体を含有する医薬組成物 |
| CL2008001933A1 (es) * | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| AU2009292615B2 (en) | 2008-09-17 | 2015-12-03 | Mylan Inc. | Granulates, process for preparing them and pharmaceutical products containing them |
| US20130172375A1 (en) * | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
| CN104428001A (zh) | 2012-03-30 | 2015-03-18 | 武田药品工业有限公司 | Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与 |
-
2015
- 2015-03-25 UY UY0001036046A patent/UY36046A/es not_active Application Discontinuation
- 2015-03-26 EA EA201691918A patent/EA031190B1/ru not_active IP Right Cessation
- 2015-03-26 ES ES15716288T patent/ES2744298T3/es active Active
- 2015-03-26 CA CA2943808A patent/CA2943808C/en active Active
- 2015-03-26 EP EP15716288.4A patent/EP3122334B1/en active Active
- 2015-03-26 BR BR112016022219-9A patent/BR112016022219B1/pt active IP Right Grant
- 2015-03-26 US US15/128,714 patent/US10426782B2/en active Active
- 2015-03-26 MA MA039765A patent/MA39765A/fr unknown
- 2015-03-26 CR CR20160483A patent/CR20160483A/es unknown
- 2015-03-26 JP JP2016558714A patent/JP6571105B2/ja active Active
- 2015-03-26 GE GEAP201514304A patent/GEP20186932B/en unknown
- 2015-03-26 CN CN201580026318.XA patent/CN106456787B/zh active Active
- 2015-03-26 PE PE2017000171A patent/PE20170773A1/es unknown
- 2015-03-26 WO PCT/US2015/022792 patent/WO2015148828A1/en not_active Ceased
-
2016
- 2016-09-23 DO DO2016000254A patent/DOP2016000254A/es unknown
- 2016-10-24 CO CONC2016/0003340A patent/CO2016003340A2/es unknown
- 2016-10-26 EC ECIEPI201684317A patent/ECSP16084317A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017511313A5 (enExample) | ||
| US10426782B2 (en) | Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation | |
| KR20190108149A (ko) | 특정 vmat2 억제제의 투여 방법 | |
| CN106137998B (zh) | 奥拉帕尼药物组合物及其制备方法 | |
| JP2015527404A5 (enExample) | ||
| US20220162610A1 (en) | Novel rna transcript | |
| CN106074414A (zh) | 一种含有鲁拉西酮的口腔崩解片及其制备方法 | |
| JP2013530212A (ja) | プラミペキソールまたはその薬学的に許容される塩を含む安定性の改善された徐放型薬学組成物 | |
| WO2012035131A1 (en) | Treatment of abl overexpressing b-cell lymphoma | |
| CA2831932A1 (en) | Combinations of akt and mek inhibitor compounds, and methods of use | |
| TW202333707A (zh) | 喹唑啉酮化合物用於治療癌症之新用途 | |
| CN103816135B (zh) | 盐酸美金刚缓释制剂及其制备方法 | |
| WO2017093444A1 (en) | Compositions for oral administration in the treatment of inflammatory bowel disease | |
| US20240190858A1 (en) | Crystalline forms, pharmaceutical compositions and methods of use thereof | |
| KR20240004589A (ko) | 소토라십 제형 | |
| CN104434853A (zh) | 一种盐酸莫西沙星片剂及其制备方法 | |
| US20240409928A1 (en) | Novel rna transcript | |
| TWI893107B (zh) | 藥物配製物 | |
| EP2437744B1 (en) | Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof | |
| CN107530331A (zh) | 一种含有吡咯并六元杂环化合物或其可药用盐的药物组合物 | |
| CN107648237B (zh) | 氨基嘧啶类化合物的药物组合物及其制备方法 | |
| EA050314B1 (ru) | Состав с соторасибом | |
| CN117222403A (zh) | 索托拉西布制剂 | |
| Lieu et al. | Patient-Focused Treatment Decisions in Metastatic Colorectal Cancer (mCRC): A Closer Look at the Role of Biomarkers in Optimizing Outcomes | |
| CN117042778A (zh) | 用于治疗方案的PI3K-δ抑制剂 |